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A B S T R A C T
Purpose: To better deﬁne the convulsive status epilepticus (CSE) as a possible manifestation at the onset
of Panayiotopoulos syndrome (PS) and to assess its prognostic value in these children.
Methods: Children with CSE and diagnostic criteria of PS were identiﬁed, followed clinically and
compared with a group of patients with PS without CSE from 1993 to 2012.
Results: We identiﬁed 37 patients with CSE at the onset of PS. During the same period we identiﬁed 72
children with autonomic symptoms of PS without CSE. The ﬁrst episode of CSE occurred at a mean age of
6.5 years. Generalized clonic seizures were the most common ictal event and one-third of the patients
required admission to Intensive Care Units. Interictal EEGs showed occipital spike activity in 31 (83.7%)
subjects. Only 14 (37.8%) patients were treated with valproic acid and for two of them (5.40%) it was
necessary to administer other drugs. There were no intractable cases. The overall prognosis was
excellent. After the ﬁrst event, 15 subjects (40.54%) experienced at least another typical PS seizure, but
all patients were seizure free at the last follow-up.
Conclusion: CSE is not uncommon in PS and it may occur at the onset of benign childhood epilepsy,
without leading to a poor prognosis.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Panayiotopoulos syndrome (PS) is a relatively common early-
onset benign childhood epilepsy, with an estimated prevalence of
around 13% of all epilepsies among 3–6 years-old children, with* Corresponding author at: Department of Pediatrics, University of Perugia,
‘‘Santa Maria della Misericordia’’ Hospital, piazzale Menghini 1, 06156 Perugia,
Italy. Tel.: +39 075 5784417; fax: +39 075 5784417.
E-mail address: averrott@unich.it (A. Verrotti).
http://dx.doi.org/10.1016/j.seizure.2014.05.013
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reone or more non-febrile seizures, and 6% in the age group between
1 and 15 years.1,2 In the late 80s, Panayiotopoulos ﬁrst described
the syndrome, deﬁning the clinical triad of vomiting, tonic eye
deviation and nocturnal seizures.3,4 Recently, PS was recognized by
the ILAE5 and subsequently conﬁrmed in independent prospective
studies.4,6 PS is characterized by an unusual variety of autonomic
symptoms and typical EEG ﬁndings. Generally, seizures start with
autonomic signs (81%), mainly vomiting (72%), occurring during
sleep (70%), alone or associated with behavioral changes, such as
loss of consciousness.7 In half of the cases, seizures lasted more
than 30 min, therefore leading to an autonomic status epilepticus,served.
Fig. 1. Right hemiconvulsive SE in a 5.5-year-boy. Ictal EEG shows high-amplitude,
repetitive spike wave complexes over the left hemisphere.
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ﬂushing or cyanosis and prolonged thermoregulatory changes,
lasting for hours.2
The EEG of patients with PS shows great variability in terms of
localization, but two-thirds of patients present a multifocal
interictal EEG with predominant occipital spikes.6 EEG foci
frequently shift and increase in number and localization. Thus,
frontal or centro-temoporal spikes, generalized discharges alone or
in combination may be present.1,8
The main features of PS are the autonomic seizures and
occasionally these autonomic symptoms can present with a
prominent impact on cardiac and respiratory functions. Mujawar
et al.9 reported the case of a 3 year-old child with a diagnosis of PS
who presented an ictal cardiorepiratory arrest requiring cardio-
pulmunary resuscitation. However, this is an extremely rare event,
with only 4 cases being reported in the literature.9
The incidence of sudden unexplained death in epilepsy (SUDEP)
is estimated to be 0.35–1.8 per 1000 patient-years and the risk is
signiﬁcantly increased (about 3–9 per 1000 patient-years) in those
with intractable epilepsy.10,11 The pathophysiology of this severe
complication of epilepsy remains unclear; however, some ictal
autonomic changes, particularly cardiac, respiratory and cerebral
mechanisms, are probably involved in the etiology of SUDEP. These
factors could directly inﬂuence the excitation of neocortical and
limbic cortices and the responses of other structures, which
represent the central autonomic network. Considering the above
mentioned mechanisms, it is reasonable to think that patients with
PS could present SUDEP as the worst complication. Based on to the
prevalence of PS and SUDEP, we could assume that this devastating
event might occur in about 1 out of 200 cases with PS.12
It seems that convulsive status epilepticus (CSE) is a rare event,
mainly at the onset of PS. There are few data suggesting that CSE in
PS is an exceptional event.13 Fejerman et al. reported two cases of
SE with electroclinical features presenting in the context of benign
partial epilepsies,14 while Ferrie et al. described a rolandic epilepsy
followed by an autonomic status epilepticus in a patient with PS at
the onset, deﬁned as an atypical evolution.15
The aim of the present multicenter study was to analyze the
electro-clinical features and long-term outcomes in a cohort of
patients with CSE at the onset of PS. In order to assess the potential
prognostic role of CSE at the onset, we compared the long-term
evolution of these patients with a group of patients with PS but
without CSE.
2. Patients and methods
A cohort of 37 patients with PS was selected in 8 neurological
and general pediatric centers from 1993 to 2012. All patients were
referred to these institutions for CSE without fever, considering
status epilepticus an event characterized by 30 min of continuous
seizure activity or at least two sequential seizures without full
recovery of consciousness between seizures.16 According to the
deﬁnition proposed by the Epilepsy Foundation of America
(Epilepsy Foundation of America’s Working Group on Status
Epilepticus, 1993),17 we considered the convulsive form of status
epilepticus deﬁned as the repeated generalized convulsive seizures
with persistent postictal depression of neurological function
between seizures or partial seizures manifested as focal motor
convulsions. All patients required hospitalization for the resolution
of the episodes and for the diagnostic and therapeutic work-up.
Data on psychomotor development before the onset of CSE, full
neurological examination and brain magnetic resonance imaging
(MRI), ictal and inter-ictal electroencephalography (EEG) record-
ings were obtained. The diagnosis of PS was made following the
electro-clinical criteria indicated by Panayiotopoulos3 and Car-
aballo et al., 4 i.e., (1) at least one afebrile seizure featuringautonomic manifestations, with or without other ictal clinical
manifestations (e.g., eye deviation, motor phenomena), followed
by impaired consciousness with secondary generalization; (2)
occipital and extra-occipital spikes at the interictal EEG; (3) normal
neurological development and (4) unremarkable brain imaging.
Once the diagnosis was made, all patients were followed for at
least 5 years. The following clinical data were analyzed: (a) age at
seizure onset, (b) treatment strategies, (c) duration of treatment,
(d) EEG ﬁndings at the onset and during follow-up and (e) clinical
outcome during and off treatment.
To compare the electro-clinical evolution of patients with CSE,
we also recruited 72 age and sex-matched children, aged 2–14
years, with PS but without having shown CSE. All children
underwent a careful neurological examination, inter-ictal EEG
and neuroimaging. The two groups were compared with regard to
the following aspects: no therapy, monotherapy, polytherapy and
seizure outcome.
Statistical analysis was conducted using SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA). Comparisons between groups were
performed with Student T-test for continuous variables and with
X2 test for categorical variables. Statistical signiﬁcance was deﬁned
as a p-value <0.05.
3. Results
3.1. Onset of CSE
Twenty-seven patients had CSE with generalized clonic
seizures, while 10 showed focal clonic seizures affecting one side
of the body or both sides alternatively.
Ictal EEGs were recorded in 20 patients (54.1%): 12 (32.4%)
children showed epileptic discharges in occipital lobes, 4 (10.8%)
also in the temporal lobes, while the other 4 patients showed only
generalized discharges (see Fig. 1). Cerebrospinal ﬂuid analysis (10
patients) was unremarkable in all cases.
All patients underwent brain MRI at the time of CSE and no
abnormalities were observed in any children.
Eleven (29.7%) children required admission to Intensive Care
Units for the intensive monitoring and treatment of CSE.
All subjects performed an interictal EEG: most subjects
(83.78%) showed occipital spike activity. Twenty-two of these
patients have not presented further events of CSE, therefore
the interictal EEG led the clinician to the diagnosis of PS. Other
5 (13.51%) patients had fronto-central, multi-focal or temporo-
occipital spike-wave foci and only 1 presented generalized
abnormalities after resolution of CSE.
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Eleven out of 37 patients (29.7%) required admission to the
Intensive Care Units for the maintenance and/or stabilization of
vital functions, to arrest seizure activity and to monitor critically ill
patients. All 11 children received one administration of benzo-
diazepines as ‘ﬁrst-line drugs’ for the treatment of the initial CSE;
speciﬁcally, 5 of them received two consecutive doses of
benzodiazepines. Given the failure of this treatment, phenytoin
(dose 20 mg/kg) was administered to nine children, while two of
them were treated with phenobarbital. None of these seizures
evolved in refractory CSE.
CSE of the remaining 26 patients resolved without the need of
intensive care. A single administration of benzodiazepines was
sufﬁcient to disrupt CSE in 20 patients, while for the remaining
9 children a second dose of benzodiazepines was necessary.
3.3. Follow-up
After resolution of CSE, 14 (37.8%) patients were treated with
monotherapy. Valproic acid (VPA) was the most common drug
administered in the 8 centers, at a dosage of 22.7  9.8 mg/kg/
day. For 2 children (5.40%) a polytherapy was required. In
particular, one patient received carbamazepine (CBZ) and clonaze-
pam, while another was treated with the association of CBZ and
oxcarbazepine (OXC), without important side effects. One patientTable 1
Electroclinical features, AED therapy and outcome of seizures in patients (n = 37)
with PS and convulsive status epilepticus (CSE) at the onset versus patients with PS





CSE at the onset
(n = 37) (n = 72)
Sex
Males, n (%) 20 (54.05%) 31 (43.05%)
Females, n (%) 17 (45.94%) 41 (56.94%)
Clinical history
Family history of seizures, n (%) 4 (10.81%) 10 (13.88%)
Personal history of seizures, n (%) – 2 (2.77%)
Psychomotor development
Normal for age, n (%) 36 (97.29%) 59 (81.94%)
Borderline IQ/language delay, n (%) 1 (2.70%) 3 (4.16%)
Age at Seizure Onset
Age at onset,
mean  SD (range), years
6.52  2.89 5.25  1.89
Ictal EEG patterns
Temporo-occipital, n (%) 12 (32.43%) 31 (43.05%)
Parieto-temporal, n (%) 4 (10.81%) 7 (9.72%)
Generalized abnormalities, n (%) 4 (10.81%) –
Interictal EEG patterns
Focal occipital paroxysms, n (%) 31 (83.78%) 64 (88.88%)
Generalized abnormalities, n (%) 1 (2.37%) –
Multiple alterationsa, n (%) 5 (13.51%) 8 (11.1%)
Intensive Care Unit Admission 11 (29.72%) –
Outcome
Response to treatment
No therapy 21 (56.75%) 69 (95.83%)
Monotherapy, n (%) 14 (37.83%) 3 (4.16%)
Add-on drugs, n (%) 2 (5.40%) –
Intractable Epilepsy. n (%) – –
Therapy at last follow-up
No therapy, n (%) 33 (89.18%) 71 (98.61%)
Monotherapy, n (%) 4 (10.81%) 1 (1.38%)
Polytherapy, n (%) – –
Follow-up duration,
mean  SD (range), years
5 years
(SD = 5.6  1.1)
8 years
(SD = 7.9  2.8)
Seizure outcome
Seizure free, n (%) 37 (100%) 71 (98.61%)
Not controlled, n (%) – 1 (1.38%)
a Multiple alterations = fronto-central, multi-focal, temporo-occipital.experienced side effects following the administration of CBZ. There
were no reported interactions with the antiepileptic drugs (AEDs)
used.
All patients had the ﬁrst follow-up assessment within 3 months
after CSE.
After CSE, considered for all subjects as the ﬁrst event, 15
patients had at least 2 more seizures with electro-clinical features
of PS in the ﬁrst 2 years of follow-up. For all other patients of the
study-group, who showed autonomic symptoms and/or interictal
EEG typical of PS immediately after CSE (within 24 h), CSE was
considered the only ictal event. The interictal EEGs (i.e.: occipital
spike activity) and/or autonomic symptoms typical of PS (i.e.: tonic
eye deviation, vomiting, etc.) led to the diagnosis.
Afterward, a strict follow-up was performed for at least 5 years
in all children: no patient was lost during follow-up (mean
duration 5.6  1.1 years). No patients presented other episodes of
CSE. All patients were seizure free at the last follow-up visit.
In all patients (except 2 subjects who showed persistence of
intermittent occipital spikes for one year), interictal EEG became
normal after around 6 months from the beginning of anticonvul-
sant therapy and persisted normal during the whole follow-up
period.
At the end of the follow-up, a comparison between the group of
patients with and without CSE was performed. No signiﬁcant
differences in any parameters were observed between the two
groups.
Table 1 shows the results for the two study groups.
4. Discussion
To our knowledge, there are no prospective studies addressing
CSE as a clinical feature of PS. Our study suggests that CSE should
be considered as one of the possible presentations of PS. Indeed,
Panayiotopoulos considered CSE as a rare event in PS, although
brief hemiconvulsions are reported in 40% of children.18,19
Sanders et al. reported a case of a 3-year-old male child with PS
who presented a status epilepticus at the onset followed by a
cardiorespiratory arrest, requiring cardiopulmonary resuscita-
tion.9 However, most of the signs and symptoms reported were
autonomic without any description of seizures at the onset of PS.
Furthermore, cardio-respiratory arrest was reported in four out of
around 1000 cases that recovered completely.13
Caraballo et al.20 reported a case who initially had typical PS but
later showed behavioral and neuropsychological impairments,
probably in association with continuous spikes and waves
recorded on EEG during sleep. Saitoh et al. reported a 10 year-
old girl who showed short consciousness alterations 4 years after
the onset of typical Panayiotopoulos seizures.21
Michael et al.23 performed a literature review to clarify features
of PS and Gastaut syndromes,in particular to assess seizure
prognosis and the clinical management of these two forms of
idiopathic epilepsies. They considered frequency of clinical
seizures, seizure semiology and frequency and location of interictal
spikes on EEG22,23 as potential prognostic factors. They found that
CSE at the onset has little effect on long-term prognosis. Even after
the most severe manifestations, all patients recovered after a few
hours of sleep. We believe that the prognosis of patients with PS is
good, independently of the type of onset, with or without CSE. At
the last follow-up, 33 (89%) out of our patients did not need any
anti-epileptic therapy.
The prognosis of a typical PS is considered excellent. Compared
to children with intractable epilepsy, those with PS are considered
to have a benign focal epilepsy, and they go into remission without
treatment with AEDs until adolescence.24 Remission often occurs
within one to two years after onset, generally before 12 years of
age. Only 5–10% of the subjects may present recurrences of
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either brief or prolonged, and they are refractory to conventional
AEDs therapy.25
In the present study, for 11 children, it was not sufﬁcient to
administer benzodiazepines to stop discharge activity and to
stabilize vital functions, but it was necessary to administer a
‘second-line drug’ to arrest prolonged seizures. None of these
patients experienced a refractory CSE, but they showed a
remarkable response to benzodiazepines associated or not to
‘second-line drugs’, with resolution of CSE. The response to
therapy was complete, without the development of epilepsy
resistant to therapy. Our patients presented a homogeneous
prognosis with complete seizure control and epilepsy remission
similar to those observed in the group of patients who did not
experience CSE. Although our patients were treated in different
neuropediatric centers, all of them were followed for a long
period of time, allowing a clear evaluation of their long-term
prognosis.
In addition, in this study 16 children received chronic AED
treatment, in particular 14 were treated with monotherapy and it
was necessary to add an AED for two children. We have already
said that the prognosis of PS is very good, therefore AED
treatment is usually not recommended for patients with a ﬁrst
seizure. However, studies conducted in different centers
demonstrated that it would be better to consider treating
patients with VPA, CBZ or clobazam after a second or third
seizure, according to the length of seizures, the association of
mild neurobehavioral disorders and if the parents agree, once
informed about chronic AED side effects.26,27 Treatment with
AEDs is associated with potential acute and chronic side effects
and relevant costs. Furthermore, it is unknown whether AED
treatment may effectively suppress epileptic EEG abnormalities
or improve cognitive and behavioral functions.28 Thus, the period
of treatment should be two to three years after the last seizure;
thereafter AEDs are discontinued, without waiting for the
disappearance of epileptic EEG spikes. In our study-group, more
than 89% of the patients had already stopped treatment at the
last follow-up and one patient was reported to have side effects
with the administration of CBZ.
In conclusion, the present study demonstrates that CSE can
occur at the onset of PS, although it is not associated with a poor
prognosis. Over the years, the concept of PS has been expanded,
and now includes a wider and larger spectrum of seizures far
beyond the occipital manifestations.29 However, many theoretical
and practical points, including diagnostic, genetic, and pathophys-
iologic issues still remain unsolved for PS and the complete
deﬁnition of PS is still a challenge. The identiﬁcation of missing
pieces in the PS puzzle will probably require a multidisciplinary
prospective and evidence-based approach.
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